Ascendis Pharma A/S
ASND
160 hedge funds and large institutions have $5.64B invested in Ascendis Pharma A/S in 2023 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 53 increasing their positions, 63 reducing their positions, and 15 closing their positions.
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
1% more funds holding
Funds holding: 158 → 160 (+2)
4% more capital invested
Capital invested by funds: $5.45B → $5.64B (+$197M)
1.33% less ownership
Funds ownership: 106.81% → 105.48% (-1.3%)
16% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 63
24% less call options, than puts
Call options by funds: $17.4M | Put options by funds: $23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$16.6M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$16.2M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$15.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$12M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$47.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$39.2M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$21.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.2M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$11.9M |
ASND Hedge Fund Activity: Q3 2023 in Review
160 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2023, worth a combined $5.64B — up 3.6% from $5.45B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ASND positions and 15 closed out — a net gain of 4 holders — while 53 added to existing stakes and 63 trimmed.
The largest buyer was Massachusetts Financial Services, adding an estimated $16.6M. The largest seller was RA Capital Management, cutting an estimated $47.3M.
- 160 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2023, up from 158 in Q2 2023.
- Funds reported $5.64B of Ascendis Pharma A/S stock for Q3 2023, up 3.6% quarter-over-quarter.
- 19 funds opened new Ascendis Pharma A/S positions in Q3 2023 and 15 closed out, a net change of +4 holders.
- The largest Ascendis Pharma A/S buyer in Q3 2023 was Massachusetts Financial Services, an estimated $16.6M added.
- The largest Ascendis Pharma A/S seller in Q3 2023 was RA Capital Management, an estimated $47.3M sold.
Based on aggregated 13F filings for Q3 2023.